ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Ghaith Abu-Zeinah reviews the risks and threats in essential thrombocythemia (Video 2/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Ghaith Abu-Zeinah reviews the risks and threats in essential thrombocythemia (Video 2/3)

    Published 1 month

    G

    Ghaith Abu-Zeinah, MD

    Medical Professional

    Risk and Threats in ET

    More in this series: ET General Education_2026
    Dr. Ghaith Abu-Zeinah explores why essential thrombocythemia matters and the current unmet needs in patient care (Video 1/3)

    Dr. Ghaith Abu-Zeinah explores why essential thrombocythemia matters and the current unmet needs in patient care (Video 1/3)

    Why ET Matters: The Unmet Need

    Ghaith Abu-Zeinah, MD
    Hematologic Malignancies
    Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)

    Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)

    When to Start Treatment in ET

    Ghaith Abu-Zeinah, MD
    Hematologic Malignancies
    Related Videos
    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Eytan Stein, MD
    Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)

    Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)

    Wade Iams, MD
    What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)

    What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)

    Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)

    Eytan Stein, MD
    Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)

    Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)

    Ghaith Abu-Zeinah, MD